胶质母细胞瘤（GBM）由于抗癌药物的血脑屏障通透性差、治疗后复发、恶性程度高等特点，是一个具有挑战性的问题，目前的治疗策略难以治疗。此外，通过常规联合治疗进行手术切除后GBM的预后和生存率仍然较差。由于强大的血脑屏障（BBB）的存在以及GBM生长的侵袭性、浸润性，GBM的诊断和治疗非常具有挑战性。近年来，脂质体及其衍生物因其生物相容性、长循环、易于物理和化学修饰等优点而成为治疗胶质母细胞瘤的疏水性和亲水性药物的超级运输工具，从而促进了治疗胶质母细胞瘤的能力。靶向特定位点，规避 BBB 运输限制，并放大治疗效果。在此，我们及时更新了新兴的基于脂质体的药物输送系统以及这些领域对脑肿瘤诊断和治疗的潜在挑战。此外，我们专注于最新的基于脂质体的药物递送货物，包括 pH 敏感、温度敏感和仿生脂质体，以增强胶质母细胞瘤成像和治疗的多模态。此外，我们还强调了基于脂质体的药物递送的研究和临床转化的未来困难和方向。希望这篇综述能够引起研究人员的兴趣，加速脂质体货物的开发，甚至其临床转化，以改善胶质母细胞瘤的预后。

Glioblastoma (GBM) is a challenging problem due to the poor BBB permeability of cancer drugs, its recurrence after the treatment, and high malignancy and is difficult to treat with the currently available therapeutic strategies. Furthermore, the prognosis and survival rate of GBM are still poor after surgical removal via conventional combination therapy. Owing to the existence of the formidable blood-brain barrier (BBB) and the aggressive, infiltrating nature of GBM growth, the diagnosis and treatment of GBM are quite challenging. Recently, liposomes and their derivatives have emerged as super cargos for the delivery of both hydrophobic and hydrophilic drugs for the treatment of glioblastoma because of their advantages, such as biocompatibility, long circulation, and ease of physical and chemical modification, which facilitate the capability of targeting specific sites, circumvention of BBB transport restrictions, and amplification of the therapeutic efficacy. Herein, we provide a timely update on the burgeoning liposome-based drug delivery systems and potential challenges in these fields for the diagnosis and treatment of brain tumors. Furthermore, we focus on the most recent liposome-based drug delivery cargos, including pH-sensitive, temperature-sensitive, and biomimetic liposomes, to enhance the multimodality in imaging and therapeutics of glioblastoma. Furthermore, we highlight the future difficulties and directions for the research and clinical translation of liposome-based drug delivery. Hopefully, this review will trigger the interest of researchers to expedite the development of liposome cargos and even their clinical translation for improving the prognosis of glioblastoma.